Aug. 16 at 5:03 AM
$KZIA The company has scope in their clinical trial to test in generally easier to treat HER breast cancer, where Celcuity had success & recent PI3K corporate activity has focused. pAX offers BBB penetration, daily tablet dosing & dual mTOR- a major advantage in breast cancer, compared to competition. The trial will focus entirely on TNBC however. No current PI3K clinical trials are being conducted in TNBC- considered just too hard, in this disease which accounts for 20% of BC. Recruitment is slower- but ultimately success in TNBC should resinate in oncology, around the world. What could be the value of a new TNBC standard of care ? "In September 2020, Gilead Sciences announced the acquisition of cancer drugmaker Immunomedics for
$21 billion. This purchase gave Gilead control of Trodelvy (sacituzumab govitecan-hziy), an antibody-drug conjugate that had received accelerated FDA approval in April 2020 for metastatic triple-negative breast cancer (mTNBC) News soon maybe.
